Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dropless cataract surgery with subconjunctival triamcinolone after phacoemulsification
ACTRN12624000521527Phase 2Not yet recruiting
- Sponsor
- Prof WengOnn Chan
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of triamcinolone, cefazolin, moxifloxacin and vancomycin in cataract (2 arms), sponsored by Prof WengOnn Chan. Primary endpoint: Post-operative inflammation after cataract surgery. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
triamcinolonecefazolinmoxifloxacinvancomycin
03
Conditions
cataract
Beyond the preview
Go deeper on ACTRN12624000521527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000521527.